1.1Polycaprolactone support films
Hot-press polycaprolactone pellets between release liners with thickness shims to form flexible sheets. Oxygen plasma increases surface wettability before application of the aqueous gelatin coating.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Hot-press polycaprolactone pellets between release liners with thickness shims to form flexible sheets. Oxygen plasma increases surface wettability before application of the aqueous gelatin coating.
Dissolve chitosan in dilute aqueous acetic acid and draw the solution across each film with a doctor blade. Dry the coating, neutralize it with dilute sodium hydroxide, and rinse it to obtain a water-insoluble coating at neutral pH.
Dry the gelatin coatings to form solid layers and confine their edges between sealed PLGA margins. A window in the tissue-facing film admits fluid, which dissolves the gelatin and releases the payload.
Disperse micronized dexamethasone acetate in an aqueous gelatin casting solution and dry it as a thin insert between the coated films. Fluid hydrates the insert, and dissolved drug diffuses through the hydrated gelatin.
Emboss shallow wells into the tissue-facing PLGA film before coating it with gelatin. Dispense a resolvin D1 solution into the coated wells after assembly and dry the deposits so that tissue fluid rehydrates them directly.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A removable culture insert holds a stack of crosslinked gelatin-coated poly(lactic-co-glycolic acid) films above a tissue explant. A resolvin D1 solution is deposited between adjacent films before assembly. A gasket seals the stack perimeter against the insert wall, and the lower face contacts the explant medium so that release occurs through the exposed face.
Solvent-cast polycaprolactone films replace the poly(lactic-co-glycolic acid) films. Oxygen plasma increases surface wettability before an aqueous gelatin coating is applied and crosslinked. Resolvin D1 is deposited between opposed gelatin surfaces, and a peripheral seam holds the films together with the central release area exposed.
Four poly(lactic-co-glycolic acid) films have nominal dry thicknesses of 20, 40, 60, and 80 micrometers. Each film receives a crosslinked gelatin coating, and equal volumes of resolvin D1 solution are placed at the three internal interfaces. The films are stacked in order of increasing thickness from the tissue-facing side. This places the outermost drug reservoir behind the thinnest film on the side facing the tissue.
Three crosslinked gelatin-coated poly(lactic-co-glycolic acid) films form two internal loading planes. A dispenser applies 0.2-microliter droplets of resolvin D1 solution on a square grid with 2-millimeter center spacing at each plane. The grid at the second plane is offset by 1 millimeter along both axes. Solvent evaporates before stacking, leaving discrete deposits distributed across the two planes.
A resorbable vascular patch carries a stack of crosslinked gelatin-coated poly(lactic-co-glycolic acid) films on its outer surface. Resolvin D1 is deposited at the internal interfaces before the laminate is attached. Sutures through the unloaded laminate margin secure the stack to the patch, with its exposed face directed toward the surrounding tissue.
A motion stage positions each crosslinked gelatin-coated poly(lactic-co-glycolic acid) film beneath a camera and a calibrated liquid dispenser. Software locates the film edges, translates a stored drop pattern to the measured film position, and triggers deposition of resolvin D1 solution inside the assembly margin. A second image checks droplet placement before a vacuum placement head aligns the next film against fixture stops.
Dissolve PLGA with a 50:50 lactide-to-glycolide molar ratio in ethyl acetate and draw the solution across a flat release liner with a doctor blade. Evaporate the solvent, vacuum-dry the resulting film, and cut it into sheets.
Hold a 5% weight-per-volume aqueous gelatin solution at 40 °C to keep it fluid. Spread it across each PLGA film with a doctor blade set to a 100 µm wet gap and dry the coating.
Contact the gelatin-coated films with an aqueous genipin solution buffered near neutral pH. Genipin reacts with primary amine groups in gelatin to form a network, and a subsequent water rinse removes residual soluble reagent.
Stack three gelatin-coated PLGA films with the mediator deposited in the central regions of both interfaces. Apply heat and pressure along clean PLGA margins with a narrow sealing die to join the stack around the loaded regions.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The coating of a sugar-coated tablet can be formed in accordance with a generally known method, for example, one in which a tablet is placed in a coating pan, followed by protective-film coating (protective coating), under-coating (subcoating), middle-coating (smoothing), glazing (coloring), and drying.A · US 2006/0182798 A1 · ¶ 37
While caplets are still popular today, the next generation of dosage forms, which offered all of these advantages of the capsule, comprised densely compacted cores that were coated with gelatin or similar glossy materials, typically in two parts having different colors.B · US 11,298,324 B2 · ¶ 5
An empty cell means only that no passage was reproduced there.
However, such preparations tend to decrease coating solubility over time, which relates to a bioavailability of an active ingredient, by, for example, cross-linking caused by interaction between a gelatin molecule and filled contents or decomposed matter thereof.A · US 2006/0182798 A1 · ¶ 5
Moreover, it is known as a general problem of a soft capsule that the adhesion thickness of a coating jointed portion cannot be sufficiently obtained when the capsule is formed, and so the strength of the capsule becomes insufficient, and the leakage of the content of the capsule, the rupture of the capsule, or the like is cuased.A · US 2006/0182798 A1 · ¶ 7
The gelatinous endcaps are provided on opposing ends of the elongated tablet core or opposing sides of a round tablet core so that they do not meet and form a circumferential gap or band through which the subcoating is visible.B · US 11,298,324 B2 · ¶ 2
The present invention furthers these earlier advances by producing an improved gelcap or geltab having faster disintegration and/or dissolution times relative to the commercially available gelatinous coated products.B · US 11,298,324 B2 · ¶ 8
patent.fyi, US 2026/0355107 A1, claim 1, first published 2026-11-19T07:53:10-05:00, https://patent.fyi/US20260355107/, SHA-256 4c844c2452fd98d39deeeb3a628605be6c266dbe3bba9cc58429b031b410daa4